Jan. 25 at 4:53 PM
$DHR "Heads up alert! Upcoming earnings on Wednesday, 1/28/2026 for
$DHR
Bullish (8.0)
---
Danaher Corporation (DHR) has demonstrated a resilient performance in the healthcare sector, positioning itself favorably against its industry peers.
With a current P/E ratio of approximately 30, Danaher trades at a premium compared to the industry average of around 25, reflecting strong investor confidence in its growth prospects.
The company has shown a commendable EPS growth rate of 12% year-over-year, driven largely by its bioprocessing and life sciences segments, which have been pivotal in expanding its revenue base.
Analysts forecast revenue growth of around 8% for the upcoming quarter, supported by solid demand in diagnostic and biotechnology markets.
Comparatively, Danaher's recent share price performance, with a 15.43% return over the past three months, indicates a positive market sentiment that outpaces the broader S&P 500 index.
The company's strategic focus on innovation, particularly in molecular testing and diagnostics, is expected to yield continued growth.
Furthermore, the recent adjustments in price targets by analysts, with some firms setting targets as high as
$270, underscore the belief in Danaher's capacity to capitalize on emerging market opportunities.
---
Regarding the upcoming earnings report, Danaher is set to release its fourth-quarter earnings on January 28, 2026.
Analysts anticipate that the company will maintain its earnings at approximately
$1.50 per share, consistent with previous year figures, indicating stability amidst a challenging market environment.
Historical performance suggests that Danaher has a strong track record of beating earnings estimates, which could bolster investor confidence further.
The consensus among analysts remains optimistic, with a majority maintaining a ""Buy"" rating, driven by expectations of robust growth in its core segments.
---
In terms of sector performance, the healthcare equipment and services sector has shown resilience, with many companies within it reporting double-digit earnings growth.
This sector has benefitted from increased demand for medical devices and diagnostic tools, particularly in the wake of ongoing public health challenges.
The overall favorable demographics and technological advancements in healthcare are expected to sustain growth momentum, positioning companies like Danaher well for future success.
- Funds were net sellers of
$DHR during the previous reporting quarter.
- Funds with large holdings in
$DHR include:
- Aristotle Capital Management LLC, MV:
$775MM. Fund Rank: 72%
www.aristotlecap.com
- Canada Pension , MV:
$474MM. Fund Rank: 76%
- D1 Capital Partners LP, MV:
$180MM. Fund Rank: 84%
- Bluespruce Investment LP, MV:
$180MM. Fund Rank: 88%
- AKRE Capital Management LLC, MV:
$173MM. Fund Rank: 54%
www.akrecapital.com
- Last 10 days performance: 2%
- Last 30 days performance: 6%
- Last 90 days performance: 9%
Some of the latest news articles:
- Title: Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings?
Publication Date: 1/23/2026 12:17:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/specialty-diagnostics-strength-drive-thermo-121700698.html?.tsrc=rss
- Title: 1 S&P 500 Stock Worth Your Attention and 2 That Underwhelm
Publication Date: 1/22/2026 4:36:20 AM, Source: yahoo
URL: https://finance.yahoo.com/news/1-p-500-stock-worth-043620923.html?.tsrc=rss
- Title: Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Publication Date: 1/21/2026 3:00:07 PM, Source: yahoo
URL: https://finance.yahoo.com/news/danaher-dhr-expected-beat-earnings-150007855.html?.tsrc=rss
- Title: Danaher (DHR) Valuation Check After Recent Share Momentum And Premium P/E Multiple
Publication Date: 1/21/2026 12:11:23 PM, Source: yahoo
URL: https://finance.yahoo.com/news/danaher-dhr-valuation-check-recent-121123362.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
